What Is Bromantane? Definition and What Research Reports

Plain-language definition

Bromantane is a synthetic chemical compound first developed in the Soviet Union and later Russia, where it has been studied and marketed under the trade name ladasten (also written Ladasten). In the Russian pharmacological literature it is classified as an "actoprotector" or "antiasthenic" agent — a category used there for substances investigated for effects on fatigue, physical work capacity and stress tolerance. Most of what is published about it comes from Russian-language journals and from animal experiments, with a smaller number of human reports. It is a small drug-like molecule, not a peptide, hormone or vitamin.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. Nothing below describes how anyone should use any substance.

What bromantane is in chemical terms

Bromantane belongs to the adamantane family — a class of compounds built around a rigid, cage-shaped hydrocarbon skeleton. The same skeleton appears in older antiviral and antiparkinsonian drugs such as amantadine and memantine, although bromantane's substituents and its reported pharmacology differ from those agents. Bromantane carries a bromophenyl group attached through an amine linkage to the adamantane core, which is why it is sometimes written in the literature as N-(4-bromophenyl)adamantan-2-amine or as its hydrochloride salt.

Because it is a lipophilic small molecule, bromantane is handled by the body through the routes typical of that class — absorption, distribution into tissue including brain, and hepatic-type metabolism — rather than through the peptidase-driven breakdown that governs peptides. Its published mechanism work has focused on the dopaminergic system, on serotonergic contributions, and on immune and cytokine readouts.

Regulatory status

Bromantane has no approved product in the United States and is not an FDA-approved drug there; material sold under the name in Western markets is typically labelled research-use-only or as a chemical, not as a medicine. Its approvals and clinical literature originate in Russia. It has also appeared historically in anti-doping contexts, and readers should note that sport-governing bodies maintain their own lists, which change over time. This paragraph is regulatory background, not legal advice.

Why bromantane is often grouped with peptides — and why that is a misuse of the term

Bromantane is frequently listed on "nootropic and peptide" catalogues and discussed in the same forum threads as Semax, Selank or other Russian-origin research compounds. The grouping is historical and cultural rather than chemical: Semax and Selank are peptides (short chains of amino acids developed at Russian institutes), and bromantane shares their country of origin, their actoprotector/antiasthenic framing, and their sparse English-language literature — but it shares none of their structure.

• Correct usage: "bromantane, an adamantane derivative" or "ladasten, a small-molecule antiasthenic studied in rodents."
• Incorrect usage: "the bromantane peptide," "bromantane amino acid sequence," or any description implying a peptide bond backbone.
• Ambiguous usage: calling bromantane a "nootropic" — a marketing-era umbrella term with no regulatory definition, applied to substances with very different mechanisms and evidence bases.

The distinction matters for interpreting literature. Peptide papers commonly report intranasal or parenteral administration and very short plasma half-lives; bromantane studies do not, and results from one class cannot be mapped onto the other.

Related terms

What the published literature reports

Dopamine-related mechanisms in animals

Several rodent studies examined how ladasten interacts with dopamine signalling. One investigation reported that ladasten induced expression of genes regulating dopamine biosynthesis across several rat brain structures, framing its action as an effect on synthesis machinery rather than simple receptor stimulation (PMID 15500036). A later paper in Neuropharmacology examined ladasten's effects on dopaminergic neurotransmission together with hippocampal synaptic plasticity in rats, linking the neurochemical work to an electrophysiological readout (PMID 17854844). Researchers also compared ladasten with the stimulant sydnocarb to ask how much of each compound's psychopharmacological profile depended on brain dopaminergic versus serotoninergic systems (PMID 20369592).

Behaviour in stress and depression-like models

A set of mouse experiments used experimental depression-like and anxious-depressive models. One study reported effects of ladasten on cytokine markers of inflammation alongside behaviour in mice with an experimental depression-like syndrome (PMID 22803040). A companion Russian-language report examined cytokine levels and behaviour in a model of anxious depression in male C57BL/6 mice (PMID 22288152). These were animal models of stress-related behaviour, not clinical depression, and the studies described group-level changes rather than outcomes in people.

Immune and lymphocyte readouts

Two reports looked at immune cells. An earlier paper examined the effect of ladasten on proliferative activity and apoptosis in peripheral blood T-lymphocytes (PMID 12596534). A 2014 study reported a correcting effect of ladasten on shifts in T-lymphocyte subpopulation composition in C57BL/6 mice subjected to an experimental anxious-depressive state (PMID 24771370). Together these form a small neuroimmune thread within the literature rather than an established clinical finding.

Cardiovascular and autonomic observations

An animal study assessed bromantane's effects on the cardiovascular and sympathetic-adrenal systems, a line of work relevant to any compound described as improving work capacity under load (PMID 10763107).

Human reports

Human data are limited. A pilot clinical trial of ladasten was published in a Russian pharmacology journal (PMID 16995430). A separate military-medicine article described neuro- and psychophysiological effects of bromantane (PMID 10998997). Both are small, older and largely unreplicated outside Russia; neither establishes efficacy by contemporary regulatory standards.

Safety Signals in Animal Studies: What Studies Report

The toxicology literature is small but explicitly titled. One study examined the toxic effect of a single treatment with bromantane on the neurological status of experimental animals, indicating that researchers looked for neurological changes after acute administration (PMID 12124651). A separate report assessed rat neurological status over a two-month course of bromantane, extending the question to repeated administration (PMID 11109517). The cardiovascular and sympathetic-adrenal study above also belongs to this safety-adjacent group (PMID 10763107). No large, modern human safety database for bromantane exists in the indexed English-language literature, and the absence of such data is itself a limitation readers should weigh.

How to read this evidence base

1. Species: the majority of cited work used rats or mice; rodent neurochemistry and behaviour do not transfer directly to humans.
2. Language and access: many papers are Russian-language with English abstracts only, limiting independent scrutiny of methods.
3. Age: several key reports date from 2000–2014; few contemporary replications appear in the indexed literature.
4. Model validity: "experimental depression-like syndrome" and "anxious-depressive state" are laboratory constructs, not diagnoses.
5. No US approval: the compound has not gone through FDA review, so no agency-reviewed labelling, dosing or safety summary exists.

For a glossary reader, the practical takeaway is definitional: bromantane is an adamantane-derived small molecule, known as ladasten in its primary literature, studied mainly in Russian animal pharmacology for dopamine-related, behavioural and immune endpoints — and it is not a peptide, despite frequent mislabelling.

References

• Toxic effect of single treatment with bromantane on neurological status of experimental animals (Bulletin of Experimental Biology and Medicine, 2002)
• The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats (Neuropharmacology, 2007)
• Effect of ladasten on proliferative activity and apoptosis in peripheral blood T-lymphocytes (Eksperimental'naia i Klinicheskaia Farmakologiia, 2002)
• The effect of bromantane on the cardiovascular and sympathetic-adrenal systems in animals (Eksperimental'naia i Klinicheskaia Farmakologiia, 2000)
• Effect of ladasten on the content of cytokine markers of inflammation and behavior of mice with experimental depression-like syndrome (Bulletin of Experimental Biology and Medicine, 2011)
• Role of the brain dopaminergic and serotoninergic systems in psychopharmacological effects of ladasten and sydnocarb (Eksperimental'naia i Klinicheskaia Farmakologiia, 2010)
• The neuro- and psychophysiological effects of bromantane (Voenno-Meditsinskii Zhurnal, 2000)
• Ladasten induces the expression of genes regulating dopamine biosynthesis in various structures of rat brain (Eksperimental'naia i Klinicheskaia Farmakologiia, 2004)
• Pilot clinical trial of ladasten (Eksperimental'naia i Klinicheskaia Farmakologiia, 2006)
• Effect of bromantane on the rat neurologic status in two month course (Eksperimental'naia i Klinicheskaia Farmakologiia, 2000)
• Correcting effect of ladasten on variations in the subpopulation composition of T lymphocytes in C57BL/6 mice on the experimental model of an anxious-depressive state (Bulletin of Experimental Biology and Medicine, 2014)
• Effect of antiasthenic drug ladasten on the level of cytokines and behavior in experimental model of anxious depression in C57BL/6 male mice (Eksperimental'naia i Klinicheskaia Farmakologiia, 2011)